TIDMABC
RNS Number : 3221A
ABCAM Plc
06 October 2009
?
Abcam plc ("Abcam" or "the Company")
PDMR Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that
markets antibodies via its own online catalogue, announces that on 5 October
2009 Jane Cooke, a PDMR of the Company, sold 5,000 ordinary shares of 1 pence
each in the Company at a price of 875p per ordinary share. Following this
transaction Mrs Cooke has an interest in 349 ordinary shares under the Company's
share incentive plan and has options over 17,794 ordinary shares under the Abcam
plc 2005 Plan which vest subject to specific performance criteria and options
over 3,375 ordinary shares under the Abcam SAYE Scheme 2006.
+-------------------------------------------+----------------------------+
| Abcam | + 44 (0) 1223 696000 |
+-------------------------------------------+----------------------------+
| | |
| Jonathan Milner, Chief Executive Officer | |
+-------------------------------------------+----------------------------+
| Jeffrey Iliffe, Chief Financial Officer | |
+-------------------------------------------+----------------------------+
| | |
+-------------------------------------------+----------------------------+
| Numis Securities | + 44 (0) 20 7260 1000 |
+-------------------------------------------+----------------------------+
| | |
| Michael Meade / Nick Westlake, Nominated | |
| Adviser | |
+-------------------------------------------+----------------------------+
| James Black, Corporate Broking | |
+-------------------------------------------+----------------------------+
| | |
+-------------------------------------------+----------------------------+
| Buchanan Communications | + 44 (0) 20 7466 5000 |
+-------------------------------------------+----------------------------+
| | |
| Mark Court / Stasa Filiplic | |
+-------------------------------------------+----------------------------+
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts,
USA, Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and
trades under the ticker symbol ABC. The Company produces and distributes its own
and third-party produced antibodies to academic and commercial users throughout
the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed
technical product data sheets. All the antibodies are sold under the Abcam brand
name and the Company's vision is to build the world's largest online resource of
high-quality and commercially viable antibodies. Abcam now has an online
catalogue of over 55,000 products, most of which are antibodies, from over 250
suppliers and employs 237 staff in its three operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSLQLFBKBBFFBD
|